Show simple item record

dc.contributor.authorRennert, RC
dc.contributor.authorJanuszyk, M
dc.contributor.authorSorkin, M
dc.contributor.authorRodrigues, M
dc.contributor.authorMaan, ZN
dc.contributor.authorDuscher, D
dc.contributor.authorWhittam, AJ
dc.contributor.authorKosaraju, R
dc.contributor.authorChung, MT
dc.contributor.authorPaik, K
dc.contributor.authorLi, AY
dc.contributor.authorFindlay, M
dc.contributor.authorGlotzbach, JP
dc.contributor.authorButte, AJ
dc.contributor.authorGurtner, GC
dc.date.available2018-05-28T19:30:29Z
dc.date.available2016-05-16
dc.date.available2016-05-16
dc.date.available2016-05-16
dc.date.available2016-05-16
dc.date.issued2016-06-01
dc.identifierpii: ncomms11945
dc.identifier.citationRennert, R. C., Januszyk, M., Sorkin, M., Rodrigues, M., Maan, Z. N., Duscher, D., Whittam, A. J., Kosaraju, R., Chung, M. T., Paik, K., Li, A. Y., Findlay, M., Glotzbach, J. P., Butte, A. J. & Gurtner, G. C. (2016). Microfluidic single-cell transcriptional analysis rationally identifies novel surface marker profiles to enhance cell-based therapies. NATURE COMMUNICATIONS, 7 (1), https://doi.org/10.1038/ncomms11945.
dc.identifier.issn2041-1723
dc.identifier.urihttp://hdl.handle.net/11343/212526
dc.description.abstractCurrent progenitor cell therapies have only modest efficacy, which has limited their clinical adoption. This may be the result of a cellular heterogeneity that decreases the number of functional progenitors delivered to diseased tissue, and prevents correction of underlying pathologic cell population disruptions. Here, we develop a high-resolution method of identifying phenotypically distinct progenitor cell subpopulations via single-cell transcriptional analysis and advanced bioinformatics. When combined with high-throughput cell surface marker screening, this approach facilitates the rational selection of surface markers for prospective isolation of cell subpopulations with desired transcriptional profiles. We establish the usefulness of this platform in costly and highly morbid diabetic wounds by identifying a subpopulation of progenitor cells that is dysfunctional in the diabetic state, and normalizes diabetic wound healing rates following allogeneic application. We believe this work presents a logical framework for the development of targeted cell therapies that can be customized to any clinical application.
dc.languageEnglish
dc.publisherNATURE PUBLISHING GROUP
dc.titleMicrofluidic single-cell transcriptional analysis rationally identifies novel surface marker profiles to enhance cell-based therapies
dc.typeJournal Article
dc.identifier.doi10.1038/ncomms11945
melbourne.affiliation.departmentSurgery (RMH)
melbourne.source.titleNATURE COMMUNICATIONS
melbourne.source.volume7
melbourne.source.issue1
melbourne.identifier.nhmrc1054472
dc.rights.licenseCC BY
melbourne.elementsid1080528
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512622
melbourne.contributor.authorFindlay, Michael
dc.identifier.eissn2041-1723
melbourne.identifier.fundernameidNHMRC, 1054472
pubs.acceptance.date2016-05-16
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record